Search results
May 20, 2020 · The present study sought to evaluate changes in PROs in the Scleroderma Lung Study (SLS) II, a randomized controlled trial comparing the safety and efficacy of mycophenolate mofetil (MMF) and oral cyclophosphamide (CYC) for treating SSc-ILD 9.
- Elizabeth R. Volkmann, Donald P. Tashkin, Holly LeClair, Michael D. Roth, Grace Kim, Jonathan Goldin...
- 2020
The data coordinating centre at the University of California, Los Angeles (UCLA, CA, USA), randomly assigned patients using a double-blind, double-dummy, centre-blocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily) for 24 months or oral cyclophosphamide (target dose 2·0 mg/kg per day) for 12 months followed by ...
- Donald P. Tashkin, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Eric C. Klee...
- 2016
Volkmann ER, Tashkin DP, LeClair H, Roth MD, Kim G, Goldin J, Clements PJ, Furst DE, Khanna D. Treatment with mycophenolate mofetil and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: Results of Scleroderma Lung Study II.
- Heather Bukiri, Elizabeth R. Volkmann
- 2022/06
- 10.1016/j.coph.2022.102211
Feb 15, 2019 · Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.
- Elizabeth R. Volkmann, Donald P. Tashkin, Myung Sim, Ning Li, Dinesh Khanna, Michael D. Roth, Philip...
- 2019
Elizabeth R. Volkmann, MD; Donald P. Tashkin, MD; Michael D. Roth, MD; Jonathan Goldin, MD, PhD; and Grace H. J. Kim, PhD BACKGROUND: Radiographic end points commonly are included in therapeutic trials for systemic sclerosis (SSc)-interstitial lung disease (ILD); however, the relationship between these outcomes and long-term mortality is unclear.
Objective: To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)-related interstitial lung disease (ILD). Methods: We included participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II.
Treatment with 1 year of oral CYC led to similar improvements in lung function in both SLS I and II, although the effects were not sustained following cessation of CYC. These results suggest that increasing the duration of ILD therapy may improve outcomes for patients with systemic sclerosis-ILD.
